The dual mechanism of tirzepatide has a synergistic impact that is strong enough to significantly lower the risk of cardiovascular events [3, 4]
A recent study found that semaglutide drugs, including Ozempic and Wegovy, may increase the risk of nonarteritic anterior ischemic optic neuropathy (NAION), a rare condition that can cause sudden, permanent vision loss
It does not make your medication stronger or weaker
declares no conflict of interest
Furthermore, although all GLP-1RAs carry the potential for causing DR secondary to rapid glucose lowering, observations of new or worsening DR within primary literature thus far have been isolated to the SUSTAIN-6 trial
Just a few years ago, GLP-1 therapy meant a weekly injection that had to be refrigerated and cost over $1,000 a month without coverage